KCM
SCLN

Kennedy Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Kennedy Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-73,203
Closed -$641K – 781
2014
Q4 		$641K Sell
73,203
-43,969
-38% -$356K 0.01% 695
2014
Q3 		$807K Buy
117,172
+64,989
+125% +$389K 0.02% 678
2014
Q2 		$274K Buy
+52,183
New +$254K 0.01% 726

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Kennedy Capital Management's SCLN Position: Q1 2015 in Review

Kennedy Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2015, closing a stake of 73,203 shares — an estimated $641K sold.

Kennedy Capital Management first reported a position in SCLN in Q2 2014 and held it in 3 quarters. The position peaked at $807K in Q3 2014. 130 funds tracked by Wall St. Rank hold SCLN as of Q1 2015.

  • Kennedy Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • Kennedy Capital Management sold 73,203 Sciclone Pharmaceuticals Inc shares in Q1 2015, an estimated $641K.
  • Kennedy Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2014 and held it in 3 quarters.
  • Kennedy Capital Management's Sciclone Pharmaceuticals Inc position peaked at $807K in Q3 2014.
  • 130 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2015.

Based on Kennedy Capital Management's 13F filing for Q1 2015, filed 7 May 2015.